Standard Dosing Schedule
Lurbinectedin (brand name Zepzelca) is administered intravenously at 3.2 mg/m² over 60 minutes on day 1 of a 21-day cycle. Patients receive this until disease progression or unacceptable toxicity.[1]
Premedication Requirements
Give dexamethasone 10 mg IV 30 minutes before each infusion, plus antiemetics like ondansetron and aprepitant to prevent nausea and vomiting.[1]
Dosage Adjustments for Toxicity
Reduce to 2.6 mg/m² (80% of starting dose) or 2.0 mg/m² (60%) for severe hematologic or non-hematologic toxicities. Withhold for grade 3/4 neutropenia, thrombocytopenia, or other grade 3/4 events until recovery to grade 1 or baseline.[1]
How Long Do Patients Stay on Treatment?
Continue cycles until progression, with median duration around 4-5 months in trials for relapsed small cell lung cancer. No fixed limit if tolerated.[1][2]
Who Approves This Schedule?
FDA approved in June 2020 for metastatic small cell lung cancer after platinum-based therapy, based on PMB trial data showing 35% overall response rate.[1][3]
Special Considerations for Liver or Kidney Issues
No adjustment for mild liver impairment (bilirubin ≤1.5x ULN); avoid in moderate/severe cases. Use caution with CrCl 30-89 mL/min; not studied below 30 mL/min.[1]
[1]: Zepzelca Prescribing Information (FDA)
[2]: PMB Trial Results (NEJM)
[3]: FDA Approval Summary